Featuring a slide presentation and related discussion from Dr Philippe Moreau, including the following topics:

General overview of anti-CD38 antibodies in therapy for multiple myeloma (MM) (0:00)
Anti-CD38 antibodies as part of first-line therapy for transplant-ineligible patients with MM (2:35)
Quadruplet versus triplet induction regimens with anti-CD38 antibodies for newly diagnosed, transplant-eligible patients with MM (7:44)
Clinical trial data with anti-CD38 antibodies for patients with MM at first relapse (13:02)
Treatment options for patients with MM at second relapse and beyond (18:09)
Subcutaneous formulations of daratumumab and isatuximab; CD38 as a target for other therapeutic strategies (21:00)

Colorectal Cancer | J Randolph Hecht, MD